2016
Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo
Cocco E, Lopez S, Black J, Bellone S, Bonazzoli E, Predolini F, Ferrari F, Schwab CL, Menderes G, Zammataro L, Buza N, Hui P, Wong S, Zhao S, Bai Y, Rimm DL, Ratner E, Litkouhi B, Silasi DA, Azodi M, Schwartz PE, Santin AD. Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. British Journal Of Cancer 2016, 115: 303-311. PMID: 27351214, PMCID: PMC4973158, DOI: 10.1038/bjc.2016.198.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsCell Line, TumorClass I Phosphatidylinositol 3-KinasesCyclin EDNA Copy Number VariationsFemaleGene Knockdown TechniquesHeterograftsHumansIn Situ Hybridization, FluorescenceIn Vitro TechniquesMiceMutationOncogene ProteinsPhosphatidylinositol 3-KinasesRNA, MessengerTissue Array AnalysisUterine NeoplasmsConceptsUterine serous carcinomaSerous carcinomaTumor growthCyclin E1 (CCNE1) gene amplificationRecurrent uterine serous carcinomaPrimary USC cell linesNovel therapeutic optionsSingle-agent treatmentIdeal therapeutic targetUSC cell linesCyclin E1 expressionUSC patientsUSC xenograftsInhibited cell growthCell cycle analysisAggressive variantTherapeutic optionsCCNE1 amplificationEndometrial tumorsCYC065Therapeutic targetClinical optionPIK3CA driver mutationsDriver mutationsXenografts
2015
An update on the current pharmacotherapy for endometrial cancer
de Haydu C, Black JD, Schwab CL, English DP, Santin AD. An update on the current pharmacotherapy for endometrial cancer. Expert Opinion On Pharmacotherapy 2015, 17: 489-499. PMID: 26629895, DOI: 10.1517/14656566.2016.1127351.Peer-Reviewed Original ResearchConceptsEndometrial cancerMainstay of treatmentCommon gynecologic malignancyCurrent conventional therapiesGynecologic malignanciesCurrent pharmacotherapyAvailable pharmacotherapiesConventional therapyCurrent therapiesEndometrial tumorsTargeted therapyImmunohistochemical characterizationRadiation therapyClinical careAggressive formNew therapiesPreclinical settingTherapyTherapeutic agentsCancerPharmacotherapyTumorsAvailable literatureHistoric treatmentTreatment
2012
Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer
El-Sahwi KS, Schwartz PE, Santin AD. Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer. Expert Review Of Anticancer Therapy 2012, 12: 41-49. PMID: 22149431, PMCID: PMC3287395, DOI: 10.1586/era.11.192.Peer-Reviewed Original ResearchConceptsType II endometrial cancerUterine serous cancerEndometrial cancerSerous cancerAggressive variantType I endometrial cancerFemale genital malignanciesUterine serous carcinomaOlder patientsGenital malignanciesMost recurrencesBetter prognosisSerous carcinomaEndometrial tumorsAggressive subsetEarly diagnosisTherapeutic markersMost carcinomasCancerCarcinomaMarkersHypertensionPostmenopausalObesityPatients
2010
Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro
Paik D, Cocco E, Bellone S, Casagrande F, Bellone M, Siegel EE, Richter CE, Schwartz PE, Rutherford TJ, Santin AD. Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro. Gynecologic Oncology 2010, 119: 140-145. PMID: 20673976, PMCID: PMC2939197, DOI: 10.1016/j.ygyno.2010.06.024.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsAntineoplastic Agents, PhytogenicATP Binding Cassette Transporter, Subfamily B, Member 1Carcinoma, PapillaryCell Line, TumorCystadenocarcinoma, SerousDose-Response Relationship, DrugDrug Screening Assays, AntitumorEpothilonesFemaleHumansPaclitaxelReceptor, ErbB-2TubulinUterine NeoplasmsConceptsLow HER-2/neu expressionHER-2/neu expressionPrimary USPC cell linesUSPC cell linesUterine serous papillary carcinomaSensitivity/resistanceNeu expressionCell linesAggressive endometrial tumorsPromising novel drugSerous papillary carcinomaΒ-tubulin IIIQuantitative RT-PCRPaclitaxel chemotherapyAdverse prognosisCarcinoma cell linesEndometrial tumorsNeu overexpressionPapillary carcinomaUSPC patientsPatupilonePapillary carcinoma cell lineP-glycoproteinNovel drugsPaclitaxel
2008
Mammaglobin B expression in human endometrial cancer
TASSI RA, BIGNOTTI E, FALCHETTI M, CALZA S, RAVAGGI A, ROSSI E, MARTINELLI F, BANDIERA E, PECORELLI S, SANTIN AD. Mammaglobin B expression in human endometrial cancer. International Journal Of Gynecological Cancer 2008, 18: 1090-1096. PMID: 18021217, DOI: 10.1111/j.1525-1438.2007.01137.x.Peer-Reviewed Original ResearchConceptsReal-time polymerase chain reactionPolymerase chain reactionG3 casesNormal endometrial cellsHuman endometrial cancerFresh frozen biopsiesSignificant higher levelsParaffin-embedded tissuesEndometrial cancerG1 casesMammaglobin BNormal endometriumEndometrial tumorsEndometrial cellsOvarian cancerFrozen biopsyNovel molecular markersB expressionNEC controlsGene expression profilingImmunohistochemistryProtein expressionProtein levelsG2 casesChain reaction
2006
Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas
Santin AD, Diamandis EP, Bellone S, Marizzoni M, Bandiera E, Palmieri M, Papasakelariou C, Katsaros D, Burnett A, Pecorelli S. Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas. American Journal Of Obstetrics And Gynecology 2006, 194: 1296-1302. PMID: 16647913, DOI: 10.1016/j.ajog.2005.10.794.Peer-Reviewed Original ResearchConceptsUterine serous papillary carcinomaSerous papillary carcinomaPapillary carcinoma patientsCarcinoma patientsEndometrioid carcinomaPapillary carcinomaKallikrein 10Benign diseaseSecretion levelsEndometrioid carcinoma patientsNormal healthy femalesTumor culturesSerous papillary tumorsCell biopsyPrimary endometrioid carcinomaNon-cancer groupExpression levelsReal-time polymerase chain reactionGene expression levelsPrimary tumor culturesAggressive variantHealthy womenCarcinoma cell linesPapillary tumorsEndometrial tumors